Andrew Bellinger, Chief Scientific Officer at Verve Therapeutics, Inc. (VERV), sold 30,000 shares at $37.42 ($1.2M) on 2021-12-22, disclosed to the SEC on 2021-12-27.
Open-market sale of $1.2M VERV by Chief Scientific Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $37.42 | 1,968 | $74K | 6.3% |
| 2 | $37.42 | 1,968 | $74K | 6.3% |
| 3 | $38.60 | 8,161 | $315K | 27.1% |
| 4 | $38.60 | 8,161 | $315K | 27.1% |
| 5 | $39.37 | 4,871 | $192K | 16.5% |
| 6 | $39.37 | 4,871 |
| $192K |
| 16.5% |
| Total | $38.70 avg | 30,000 | $1.2M | 100% |
| Filing → |
| VERV | SELL | 2022-09-27 | $4.2M | — | Filing → |
| VERV | SELL | 2022-07-22 | $698K | — | Filing → |
| VERV | SELL | 2022-07-15 | $249K | — | Filing → |